Skip to content
Screener

Arrowhead Pharmaceuticals, Inc. ARWR Q4 2026 Annual earnings

Reported November 12, 2026 · After market close

Revenue$37.8MMiss by $23.4M
EPS-$3.04Miss by $1.52
Revenue estimate$61.2M
EPS estimate-$1.52

Next report

Feb 4, 2027 (in 3 months)
Revenue estimate$40.8M
EPS estimate-$1.46

Financials

Q4 2026

Income statement

See full
Revenue$37.8M-85.3%
Operating income-$436.6M-1,090%
Net income-$428.0M-1,702%
EPS (diluted)-$3.01-1,572%

Balance sheet

See full
Cash & equivalents$62.7M-72.3%
Total debt$121.3M+8.9%
Total equity$50.3M-89.2%
Total assets$1.7B+25.5%

Cash flow

See full
Operating cash flow-$192.4M-1,039%
CapEx$3.4M-54.2%
Free cash flow-$195.8M-1,606%

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$6.96B+26.2%
Enterprise value$7.01B+30.0%
P/S15.4×+8.8×

Profitability

See full
Operating margin-156.9%-169pp
Net margin-160.6%-161pp
FCF margin-63%—

Returns & leverage

See full
Return on equity-280.5%-281pp
Debt / equity2.4×+2.2×
Current ratio4.1×-0.7×

FAQ

When did Arrowhead Pharmaceuticals, Inc. report Q4 2026 earnings?
Arrowhead Pharmaceuticals, Inc. (ARWR) reported Q4 2026 earnings on November 12, 2026 after market close.
What were Arrowhead Pharmaceuticals, Inc.'s Q4 2026 revenue and EPS?
Arrowhead Pharmaceuticals, Inc. reported revenue of $37.8M and eps of $-3.04 for Q4 2026.
Did Arrowhead Pharmaceuticals, Inc. beat estimates in Q4 2026?
Revenue missed the consensus estimate of $61.2M by $23.4M. EPS missed the consensus estimate of $-1.52 by $1.52.
How did Arrowhead Pharmaceuticals, Inc.'s Q4 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 85.3% from $256.5M a year earlier and eps declined 1588.9% from $-0.18.
Where can I find Arrowhead Pharmaceuticals, Inc.'s Q4 2026 SEC filings?
You can read the 8-K earnings release (0000879407-26-000077) and the 10-K periodic report (0000879407-26-000078) directly on SEC EDGAR. The filing index links above go to sec.gov.